Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | PADI1 | Q9ULC6 | 1/20 | 0.38 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.34 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.34 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.33 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9087675 | 0.98 | SMN1; SMN2 (0.44) | SMN1; SMN2PADI1PADI4SLC6A2CHRM5 | |
| SCHEMBL27972835 | 0.92 | SMN1; SMN2 (0.41) | SMN1; SMN2PADI1PADI4SLC6A2CHRM5 | |
| SCHEMBL3964702 | 0.83 | PIK3CD (0.33) | MEN1KMT2A | |
| SCHEMBL28343762 | 0.80 | SMN1; SMN2 (0.49) | SMN1; SMN2PADI1PADI4SLC6A2CHRM5 | |
| SCHEMBL8972570 | 0.80 | SMN1; SMN2 (0.44) | SMN1; SMN2PADI1PADI4SLC6A2CHRM5 | |
| SCHEMBL24462563 | 0.78 | SMN1; SMN2 (0.47) | SMN1; SMN2PADI1PADI4SLC6A2CHRM5 | |
| SCHEMBL11268764 | 0.78 | SMN1; SMN2 (0.47) | SMN1; SMN2PADI1PADI4SLC6A2CHRM5 | |
| SCHEMBL31586817 | 0.78 | SMN1; SMN2 (0.41) | SMN1; SMN2PADI1PADI4CHRM5CHRM3 | |
| SCHEMBL27841858 | 0.78 | MEN1 (0.44) | SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL18390917 | 0.77 | SMN1; SMN2 (0.46) | SMN1; SMN2PADI1PADI4SLC6A2CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624019-B2 | Indazole derivative, and preparation method therefor and use thereof | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2026-05-12 | — | — | US | disclosed |
| CN-115232108-B | SOS1 degradation agent and preparation method and application thereof | 领泰生物医药(绍兴)有限公司 | 2025-04-18 | — | — | CN | disclosed |
| CN-119431366-A | IRAK4 degradation agent compound and application thereof | 江苏先声药业有限公司 | 2025-02-14 | — | — | CN | disclosed |
| US-20240261417-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2024-08-08 | — | — | US | disclosed |
| US-20240261418-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2024-08-08 | — | — | US | disclosed |
| EP-4328219-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) | 2024-02-28 | — | — | EP | disclosed |
| EP-4328219-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) | 2024-02-28 | — | — | EP | disclosed |
| CN-115232114-B | SOS1 degradation agent and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2023-12-19 | — | — | CN | disclosed |
| EP-4238968-A1 | INDAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Leadingtac Pharmaceutical Co., Ltd. (CN) | 2023-09-06 | — | — | EP | disclosed |
| EP-4238968-A1 | INDAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Leadingtac Pharmaceutical Co., Ltd. (CN) | 2023-09-06 | — | — | EP | disclosed |
| WO-2022223033-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海领泰生物医药科技有限公司 | 2022-10-27 | — | — | WO | disclosed |
| WO-2022223034-A1 | SOS1 DEGRADATION AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海领泰生物医药科技有限公司 | 2022-10-27 | — | — | WO | disclosed |
| CN-115232108-A | SOS1 degradation agent and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-115244042-A | Indazole derivative and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-115232114-A | SOS1 degradation agent and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-115232111-A | SOS1 degradation agent and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2022-10-25 | — | — | CN | disclosed |
| US-20220306603-A1 | TARGETING DNA REPAIR IN TUMOR CELLS VIA INHIBITION OF ERCC1-XPF | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2022-09-29 | — | — | US | disclosed |
| WO-2022088551-A1 | INDAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海领泰生物医药科技有限公司 | 2022-05-05 | — | — | WO | disclosed |
| WO-2022088551-A1 | INDAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海领泰生物医药科技有限公司 | 2022-05-05 | — | — | WO | disclosed |
| EP-0049683-A2 | Imidazo-rifamycines, process for their preparation, pharmaceutical preparations containing them and their use | CIBA-GEIGY AG (CH) | 1982-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240261418-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SOS1, RAC1, RSU1 | SMN1; SMN2 1503/4885PADI1 3650/4885PADI4 4521/4885 |
| US-12624019-B2 | Indazole derivative, and preparation method therefor and use thereof | IRAK4, IRAK1, IRAK2 | SMN1; SMN2 3470/4885PADI1 1477/4885PADI4 1662/4885 |
| US-20240261417-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | RAC1, SOS1, RSU1 | SMN1; SMN2 1681/4885PADI1 3771/4885PADI4 4532/4885 |
| US-20220306603-A1 | TARGETING DNA REPAIR IN TUMOR CELLS VIA INHIBITION OF ERCC1-XPF | ERCC4, ERCC1, ERCC2 | SMN1; SMN2 2606/4885PADI1 2725/4885PADI4 4250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.